We love being on board with a great new venture right from inception. That’s our privilege with GentiBio, a brand new biotherapeutics company that just closed a $20 million seed round led by OrbiMed, Novartis Venture Fund and RA Capital Management.

Based in Boston and Israel, GentiBio is doing amazing work engineering regulatory T cells to treat autoimmune and other categories of diseases. In our role, we’ll have the opportunity to establish immaculate financial records from the outset, and provide strategic input when GentiBio needs it. We’re here to help the company grow intelligently, nail milestones, secure more funding and realize its huge potential. Read more on BioSpace.